Edition:
United States

Ocera Therapeutics Inc (OCRX.OQ)

OCRX.OQ on NASDAQ Stock Exchange Global Market

1.25USD
21 Jul 2017
Change (% chg)

$-0.01 (-0.79%)
Prev Close
$1.26
Open
$1.25
Day's High
$1.26
Day's Low
$1.24
Volume
31,280
Avg. Vol
81,875
52-wk High
$3.15
52-wk Low
$0.54

OCRX.OQ

Chart for OCRX.OQ

About

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine... (more)

Overall

Beta: 2.33
Market Cap(Mil.): $33.14
Shares Outstanding(Mil.): 26.51
Dividend: --
Yield (%): --

Financials

  OCRX.OQ Industry Sector
P/E (TTM): -- 11.79 15.85
EPS (TTM): -1.15 -- --
ROI: -104.92 -10.04 -8.31
ROE: -129.57 -9.89 -7.95

BRIEF-Ocera Therapeutics reports Q1 loss per share $0.28

* Ocera Therapeutics reports first quarter 2017 financial results and provides clinical update

May 09 2017

BRIEF-Perceptive Advisors reports 9.11 pct passive stake in Ocera Therapeutics

* Perceptive Advisors Llc reports 9.11 percent passive stake in Ocera Therapeutics Inc as of March 8, 2017- sec filing Source text - http://bit.ly/2oFR2tW Further company coverage:

Apr 17 2017

BRIEF-Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002

* Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002 in patients with hepatic encephalopathy

Mar 08 2017

BRIEF-Ocera announces top-line results for phase 2b study in hepatic encephalopathy

* Ocera announces top-line results for phase 2b study in hepatic encephalopathy

Jan 30 2017

Competitors

Earnings vs. Estimates